Bristol Myers Squibb
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Beyond's analysis on Bristol Myers Squibb
- — Atrium Therapeutics advances its cardiovascular pipeline with IND clearance for ATR 1072 and milestone payment from Bristol Myers Squibb collaboration
- — Bristol Myers Squibb's dividend safety is under scrutiny, potentially shaking investor confidence in the pharma sector
Recent news mentioning Bristol Myers Squibb
- — Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
- — Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
- — Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- — Bristol Myers Squibb to build $2.3 billion Houston campus
- — Pharmakonzern: Keine Fusionsgespräche zwischen AstraZeneca und Bristol Myers Squibb
- — AstraZeneca and Bristol Myers Squibb merger talks denied
- — Stocks to Watch Recap: Bristol Myers Squibb, Alibaba, Palantir
- — Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- — AstraZeneca, Bristol Myers Squibb exploring merger talks
- — AstraZeneca Shares Drop, Bristol Myers Squibb’s Climb After Merger Talks Reports